摘要
面对非生物抗风湿药物(DMARDs)无效或疗效减退,幼年特发性关节炎(JIA)患儿迫切需要新的治疗方法。目前已应用于JIA治疗的生物制剂主要包括:针对参与免疫炎性反应重要致炎因子(如TNF-α、IL-1、IL-6等)的抗体;针对参与免疫应答信号分子[如细胞素性T淋巴细胞相关抗原4(CTLA-4)]的抗体;针对重要免疫细胞(如B淋巴细胞)的抗体。生物制剂的问世为JIA的治疗提供了新的希望。
In the face of the ineffectiveness of non-biological anti-rheumatism drugs （DMARDs）, children with juvenile idiopathic arthritis（JIA） need to receive new treatments. Biological agents which have been used in the treatment of JIA include： antibodies against important cytokines participating in the immune inflammatory reaction such as TNF, IL-1, IL-6; antibodies against immune response signaling molecules （cytotoxic T lymphocyte-associated antigen-4, CTLA-4） ; antibod- ies against essential immune cells （such as B lymphocytes ）. Biological agents provide a new hope in the treatment for JIA.
出处
《中国实用儿科杂志》
CSCD
北大核心
2015年第9期666-672,共7页
Chinese Journal of Practical Pediatrics
关键词
生物制剂
幼年特发性关节炎
治疗
biological agents
juvenile idiopathic arthritis
treatment
